Mutational Damages in Malignant Lung Tumors.

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Genomic changes are key drivers of cancer development, growth, and progression.
• Advances in genomic analysis enable the identification of alterations influencing lung cancer treatment outcomes.

Purpose of the Study:

• To identify mutations in oncogenes and cell division genes characteristic of malignant lung tumors.
• To analyze the prevalence and significance of specific mutations in lung cancer.

Main Methods:

• Examined 400 postoperative lung tumor samples for mutations in p53, HRAS, p21Waf1, and MDM2.
• Utilized polymerase chain reaction (PCR) and reverse transcription PCR (RT-PCR) for gene and mRNA amplification and analysis.
• Employed restriction enzymes (EcoR1, Pst1) to analyze p53 and p21Waf1 mRNA.

Main Results:

• p53 or p21Waf1 expression observed in 50% of squamous cell carcinomas and adenocarcinomas.
• HRAS mutations were prevalent in most lung squamous cell carcinomas and adenocarcinomas.
• EGFR mutations (exons 19 and 21) found in 65/263 samples indicated sensitivity to EGFR tyrosine kinase inhibitors, with specific mutations more common in adenocarcinoma.

Conclusions:

• Detected mutations in lung squamous cell carcinomas and adenocarcinomas can serve as diagnostic markers.
• Genomic alterations identified can predict disease severity and response to targeted therapies.